Clinical Evaluation of the SNaP Wound Care System in Promoting Healing in Chronic Wounds
Withdrawn
- Conditions
- Lower Extremity Diabetic Leg WoundsLower Extremity Venous Leg WoundsLower Extremity Mixed Aetiology Leg Wounds
- Registration Number
- NCT01417208
- Lead Sponsor
- KCI USA, Inc
- Brief Summary
The purpose of this study is to evaluate a novel topical negative pressure (TNP) wound therapy device called the SNaP® (Smart Negative Pressure) Wound Care System for the treatment of lower extremity diabetic, venous and mixed aetiology leg wounds.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patient has diabetic foot ulceration, venous ulcer, or mixed aetiology ulcer with a surface area <100 cm2 and <10 cm in widest diameter on lower extremity, but larger than 1 cm2 (venous and mixed aetiology ulcers will be defined by clinical exam of treating physician. Diabetic foot ulcers will be defined by clinical exam of the treating physician and as lower extremity ulcers in patients with a diagnosis of diabetes, but without venous stasis disease).
- Wound present for >30 days.
- Patient has wound in location amenable to creation of airtight seal around wound using TNP dressings.
- Patient is able to comply with study protocol requirements.
- Patient is able to understand and provide written consent.
Exclusion Criteria
- Patient has evidence of wound infection in the opinion of the physician.
- Patient has a thick eschar that persists after wound debridement.
- Patient has an HbA1C >12%.
- Patient has ulcers due to inflammatory conditions such as pyoderma gangrenosum, rheumatoid arthritis, vasculitis, cryoglobulinaemia, necrobiosis lipoidica, panniculitis, lupus erythematosus, scleroderma, or calcinosis.
- Patient has untreated osteomyelitis.
- Patient has any other condition that, in the opinion of the investigator, makes the patient inappropriate to take part in this study.
- Patient is allergic to the wound care device or occlusive dressing.
- Patient has exposed blood vessels.
- Patient is pregnant or pregnancy is suspected.
- Patient is actively participating in other clinical trials that may interfere with their participation in this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Wound Closure 12 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does SNaP® TNP therapy modulate in diabetic and venous leg wound healing?
How does SNaP® compare to standard TNP devices in healing rates for mixed aetiology chronic wounds?
Which biomarkers correlate with SNaP® efficacy in patients with diabetic or venous ulcers?
What adverse events are reported with SNaP® use in chronic wound management and how are they mitigated?
Are there combination therapies or competitor devices (e.g., VAC) that enhance chronic wound healing outcomes with SNaP®?
Trial Locations
- Locations (1)
Section of Wound Healing
🇬🇧Cardiff, Wales, United Kingdom
Section of Wound Healing🇬🇧Cardiff, Wales, United Kingdom